A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

Summary

This study is to evaluate the efficacy of the LM-302 Combination With Other Therapies in patients with CLDN18.2-positive Advanced Digestive Tract Tumor.

Conditions

• Malignant Neoplasms of Digestive Organs

Interventions

DRUG

LM-302

Q2W/Q3W，Administered intravenously

DRUG

Toripalimab

Q2W/Q3W,Administered intravenously

DRUG

Capecitabine

BID,Oral Administration

DRUG

Tegafur, Gimeracil and Oteracil Potassium Capsules

BID,Oral Administration

DRUG

Nivolumab

Q4W,Administered intravenously

DRUG

Apatinib

QD,Oral Administration

DRUG

Gemcitabine

Q4W,Administered intravenously

Sponsors & Collaborators

• LaNova Medicines Zhejiang Co., Ltd.

  lead INDUSTRY

Principal Investigators

• Jin Li · Shanghai East Hospital

• Jieer Ying · Zhejiang Cancer Hospital

• Haiping Jiang · Zhejiang University

• Rushen Zhao · Zibo Municipal Hospital

• Chunmei Bai · Peking Union Medical College Hospital

• Hongming Pan · Sir Run Run Shaw Hospital

• Jing Dai · Zhongnan Hospital

• Yiping Mou · Zhejiang Provincial People's Hospital

• Haijiao Yan · The First People's Hospital of Changzhou

• Aiping Zhou · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

• Xianglin Yuan · Tongji Hospital

• Yabin Xia · First Affiliated Hospital of Wannan Medical College

• Mingzhu Huang · Fudan University

• Lixin Wan · Nanyang Central Hospital

• Jun Zhou · Shanghai Gaobo Cancer Hospital

• Youwei Zhang · Xuzhou Central Hospital

• Ning Wu · Shanghai Pudong New District Gongli Hospital

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

SEQUENTIAL

Eligibility

Min Age

18 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2023-07-27

Primary Completion

2026-07-01

Completion

2028-07-01

Countries

• China

Study Locations